Literature DB >> 33058182

Outcomes in unilateral primary aldosteronism after surgical or medical therapy.

Troy H Puar1, Lih M Loh2, Wann J Loh1, Dawn S T Lim2, Meifen Zhang1, Pei T Tan3, Lynette Lee1,2, Du S Swee2, Joan Khoo1, Donovan Tay4, Sarah Y Tan1,2, Ling Zhu2, Linsey Gani1, Thomas F King1, Peng C Kek2, Roger S Foo5,6.   

Abstract

CONTEXT: Studies find surgery superior to medications in the treatment of primary aldosteronism (PA). It would be ideal to compare surgical and medical therapy in patients with unilateral PA only, who have the option between these treatment modalities. However, this is challenging as most patients with unilateral PA on adrenal vein sampling (AVS) undergo surgery.
OBJECTIVE: To compare outcomes of surgery and medications in patients with confirmed or likely unilateral PA.
DESIGN: Retrospective cohort study of 274 patients with PA managed at two referral centres from 2000 to 2019. PATIENTS: 154 patients identified with unilateral PA using AVS and a validated clinical prediction model were treated with surgical (n = 86) or medical (n = 68) therapy. MEASUREMENTS: Primary outcome was a composite incident cardiovascular event comprising acute myocardial infarction, coronary revascularization, stroke, atrial fibrillation or congestive cardiac failure. Secondary outcomes were clinical and biochemical control.
RESULTS: Cardiovascular outcomes were comparable, with the surgery group having an adjusted hazard ratio of 0.93 (95% CI: 0.32-2.67), p = .89. Both treatments improved clinical and biochemical control, but surgery resulted in better systolic blood pressure, 133.0 ± 11.7 mmHg versus 137.9 ± 14.6 mmHg, p = .02, and lower defined daily dosages of antihypertensive medications, 1.0 (IQR 0.0-2.0) versus 2.6 (IQR 0.8-4.3), p < .001. In addition, 12 of 86 patients in the surgery group failed medical therapy before opting for surgery.
CONCLUSION: In patients with unilateral PA who can tolerate medications, medical therapy improves clinical and biochemical control, and may offer similar cardiovascular protection. However, surgery reduces pill burden, may cure hypertension and is recommended for unilateral PA.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  adrenal vein sampling; adrenalectomy; mineralocorticoid receptor antagonists; myocardial infarction; secondary hypertension; stroke

Year:  2020        PMID: 33058182     DOI: 10.1111/cen.14351

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  5 in total

1.  Curable congestive heart failure in patients with primary aldosteronism: two cases reports.

Authors:  Zijun Chen; Zhe Zhang; Qianlan Xi; Guimei Huang; Liya Wang
Journal:  Am J Transl Res       Date:  2022-04-15       Impact factor: 4.060

Review 2.  Cerebro-Cardiovascular Risk, Target Organ Damage, and Treatment Outcomes in Primary Aldosteronism.

Authors:  Xiao Lin; Muhammad Hasnain Ehsan Ullah; Xiong Wu; Feng Xu; Su-Kang Shan; Li-Min Lei; Ling-Qing Yuan; Jun Liu
Journal:  Front Cardiovasc Med       Date:  2022-02-02

3.  Primary Aldosteronism More Prevalent in Patients With Cardioembolic Stroke and Atrial Fibrillation.

Authors:  Van Nguyen; Tian Ming Tu; Marlie Jane B Mamauag; Jovan Lai; Seyed Ehsan Saffari; Tar Choon Aw; Lizhen Ong; Roger S Y Foo; Siang Chew Chai; Shaun Fones; Meifen Zhang; Troy H Puar
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-19       Impact factor: 6.055

4.  Composite Cardiovascular Outcomes in Patients With Primary Aldosteronism Undergoing Medical Versus Surgical Treatment: A Meta-Analysis.

Authors:  Wei-Chieh Huang; Ying-Ying Chen; Yen-Hung Lin; Jeff S Chueh
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-17       Impact factor: 5.555

5.  Improvement in quality of life and psychological symptoms after treatment for primary aldosteronism: Asian Cohort Study.

Authors:  Yen Kheng Tan; Yu Heng Kwan; David Choon Liang Teo; Marieke Velema; Jaap Deinum; Pei Ting Tan; Meifen Zhang; Joan Joo Ching Khoo; Wann Jia Loh; Linsey Gani; Thomas F J King; Eberta Jun Hui Tan; Shui Boon Soh; Vanessa Shu Chuan Au; Tunn Lin Tay; Lily Mae Quevedo Dacay; Keng Sin Ng; Kang Min Wong; Andrew Siang Yih Wong; Foo Cheong Ng; Tar Choon Aw; Yvonne Hui Bin Chan; Khim Leng Tong; Sheldon Shao Guang Lee; Siang Chew Chai; Troy Hai Kiat Puar
Journal:  Endocr Connect       Date:  2021-07-26       Impact factor: 3.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.